AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 261 min read$OCUL

Dugel Pravin sold $233K of OCUL

Dugel Pravin (See Remarks) sold 21,649 shares of OCULAR THERAPEUTIX, INC (OCUL) at $10.77 ($0.23M total) on 2026-08-24 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Dugel Pravin
Published Aug 26, 2026, 9:56 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 26, 2026, 10:25 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$OCUL
Neutral
medium confidence
Mentioned
$OCUL
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$OCULNeutralLow
01

Why it matters

The disclosed sale is the first public report of this transaction, providing new data for investors monitoring insider activity.

02

Market read

Provides fresh insider‑sale information; modest relevance for short‑term traders.

03

What to watch

Potential upcoming clinical data releases could offset any short‑term sell pressure.

Relevance 3/10Novelty 4/10Timing: post‑market filing

Background

Form 4 filings disclose insider transactions; a 10b5‑1 plan indicates pre‑scheduled sales.

Company-level read

Ticker impact

$OCULNeutralMedium confidence
Context

Officer/director Dugel Pravid sold 21,649 shares for $233K via a 10b5‑1 plan, reducing his stake to 2.5M shares.

Expected impact

Minor downward pressure, likely within normal volatility range.

Evidence & confidence

Sale size is modest relative to total holdings and market cap; executed under a pre‑arranged plan, so no strong directional implication.

Market effects

Sector

None significant for the ophthalmology biotech sector.

Regional

No regional effect.

Global

Limited to OCUL shareholders.

Counterpoint

What could challenge this read

The sale could be a routine liquidity event, not a negative signal.

Key entities

  • Company
    OCULAR THERAPEUTIX, INC.

    NASDAQ‑listed ophthalmology biotech.

  • Insider
    Dugel Pravin

    Officer and director of OCUL.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

OCUL insider trading history →

Related articles

SEP 3
$OCULMedAI 8/10

Ocular Therapeutix (OCUL): Faster Path To Approval Comes With Rising Costs

Ocular Therapeutix (OCUL) reported Q2 2026 results, highlighting AXPAXLI's progress for wet age-related macular degeneration. The FDA confirmed the NDA filing timeline, with potential for a faster review. Costs rose, with R&D at $54.1M, marketing at $17.3M, and net loss widening to $78.8M. Cash reserves decreased to $598.6M. AXPAXLI's data suggests fewer patient injections, and early market research shows high adoption potential. Institutional interest grew, but short interest remains high.

insidermonkey.com3 min
AUG 21
$BMYMedAI 8/10

Pharmaceuticals Stocks Q2 Highlights: Ocular Therapeutix (NASDAQ:OCUL)

Bristol-Myers Squibb (BMY) reported Q2 revenues of $12.97B, up 5.7% YoY, beating estimates. Zoetis (ZTS) reported flat revenues of $2.47B, missing estimates. Amphastar (AMPH) reported $183.9M in revenues, up 5.4% YoY, beating estimates. Eli Lilly (LLY) reported $22.97B in revenues, up 47.7% YoY, beating estimates. Market sentiment has shifted from AI to geopolitics.

finance.yahoo.com3 min
AUG 21
$MRNAHighAI 9/10

After Moderna’s Big News, Here Are Three Biotechs to Watch

Moderna (MRNA) and Merck (MRK) rose sharply after positive Phase 3 trial data for a skin cancer therapy. Biotech sector, up 40% YTD, saw gains. Aurinia (AUPH) settled litigation with Teva (TEVA), removing uncertainty. Ocular (OCUL) received positive analyst ratings. Precigen (PGEN) reported strong Q2 revenue and expects cash flow breakeven by year-end.

pro.thestreet.com3 min